Related Experiment Videos
[A case of cryptococcal meningitis successfully treated with miconazole and CSF drainage]
Abstract:
Cryptococcal meningitis is the most frequent fungal infection of the central nervous system, known readily to complicate with immuno-compromised patients. There are only a few cases of primary infection in healthy non-immuno-compromised patients. Amphotericin-B (AMPH-B) and 5-Fluorocytosine (5-FC) are effective agents against Cryptococcal meningitis, although, their toxicity and drug resistance are limiting factors. However, in recent years Miconazole has been widely used against fungal infections and it's effectiveness has been reported. This is a 68 y.o. male who was admitted to Toyohashi Municipal Hospital on March 15, 1987 because of headache, vomiting, diplopia and gait disturbance. Continuous lumbar drainage was performed since lumbar puncture revealed surprisingly high cerebrospinal fluid (CSF) pressure and presence of many Cryptococcus neoformans, i.v. AMPH-B and p.o. 5-FC was also administrated. A 7 day course of i.v. AMPH-B and p.o. 5-FC showed no improvement with side effects of macrohematuria and anorexia. Then Miconazole was administrated i.v. and intrathecal (i.t.). The clinical signs and CSF laboratory data improved after a 90 day course of Miconazole therapy and the patient was discharged on August 24. But the patient was readmitted from March 10 to April 30, 1988, because of a slight increase of C. neoformans in CSF (17/mm3) and improved by i.v. and i.t. Miconazole. The total Miconazole dosage was 90.6 g (i.t.: 505 mg) at the first admission and 36 g (i.t.: 50 mg) at the second admission, but no side effect was seen. The reduction of elevated CSF pressure with continuous CSF drainage was also important for the treatment of such cases with increased intracranial pressure.
Insights
This case study highlights Miconazole as a viable treatment for Cryptococcal meningitis in a non-immunocompromised patient. Miconazole effectively treated the fungal infection and improved symptoms when standard therapies failed.
Area of Science:
- Infectious Diseases
- Mycology
- Neurology
Background:
- Cryptococcal meningitis is a severe fungal infection primarily affecting immunocompromised individuals.
- Standard treatments like Amphotericin-B and 5-Fluorocytosine have limitations due to toxicity and drug resistance.
- Miconazole is emerging as an effective antifungal agent for various fungal infections.
Observation:
- A 68-year-old male presented with symptoms of cryptococcal meningitis, including high cerebrospinal fluid (CSF) pressure.
- Initial treatment with intravenous Amphotericin-B and oral 5-Fluorocytosine showed no improvement and caused side effects.
- Miconazole administered intravenously and intrathecally led to clinical and laboratory improvements.
Findings:
- A 90-day course of Miconazole therapy resolved the cryptococcal meningitis, with no adverse effects observed.
- The patient experienced a recurrence but responded well to a subsequent Miconazole treatment course.
- Continuous CSF drainage was crucial for managing elevated intracranial pressure.
Implications:
- Miconazole demonstrates significant efficacy and safety for treating cryptococcal meningitis, even in non-immunocompromised patients.
- This case suggests Miconazole as a potential alternative or adjunct therapy when conventional treatments are ineffective or poorly tolerated.
- Effective management of intracranial pressure is vital for successful treatment outcomes in cryptococcal meningitis.